VISIPAQUE™ (iodixanol) Injection, 5,5'-[(2-hydroxy-1,3-propanediyl)bis (acetylimino)]bis[N,N'-bis(2,3-dihydroxypropyl)-2,4,6- triiodo-1,3- benzenedicarboxamide], is a dimeric, isosmolar, nonionic, water-soluble, radiographic contrast medium with a molecular weight of 1550.
VISIPAQUE Injection (270 mgI/mL) is indicated for intra-arterial digital subtraction angiography.
VISIPAQUE Injection (320 mgI/mL) is indicated for angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography.
INTRAVENOUS For information on the concentrations and doses for the pediatric population see the Precautions–Pediatric Use, Clinical Pharmacology–Special Populations, and Dosage and Administration sections.
VISIPAQUE Injection (270 mgI/mL) is indicated for CECT imaging of the head and body, excretory urography, and peripheral venography.
VISIPAQUE Injection (320 mgI/mL) is indicated for CECT imaging of the head and body, and excretory urography.
Media Articles Related to Visipaque (Iodine Intravascular)
Tiny robotic 'hands' could improve cancer diagnostics, drug delivery
Source: IT / Internet / E-mail News From Medical News Today [2015.02.06]
Many people imagine robots today as clunky, metal versions of humans, but scientists are forging new territory in the field of 'soft robotics.
New diagnostic test for bowel diseases
Source: Irritable-Bowel Syndrome News From Medical News Today [2014.03.31]
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created by a group of researchers in the UK.
Scientists at Mainz University identify a new population of regulatory T-cells
Source: Allergy News From Medical News Today [2015.02.11]
Discovery improves understanding of the cause of allergic asthma and may serve as an early diagnostic markerWhen the mucosal surfaces in the lungs of healthy people come into contact with...
Chronic fatigue syndrome renamed and redefined
Source: Primary Care / General Practice News From Medical News Today [2015.02.11]
A committee convened by the Institute of Medicine proposes new diagnostic criteria and a new name for the condition that affects up to 2.5 million Americans.
MRI technique developed for nonalcoholic fatty liver disease in children
Source: Liver Disease / Hepatitis News From Medical News Today [2015.02.09]
Study makes strides toward noninvasive diagnostic for increasingly common pediatric liver diseaseThis is an MRI of child's liver with severe NAFLD -- 38 percent is fat whereas 1 percent is normal.
Published Studies Related to Visipaque (Iodine Intravascular)
Alcohol-based chlorhexidine vs. povidone iodine in reducing skin colonization prior to regional anesthesia procedures. [2011.07]
CONCLUSION: For skin disinfection prior to the neuraxial blockade procedure, the use of alcohol-based chlorhexidine compared with the use of povidone iodine lowered the incidence of insertion-site-colonization.
MDCT angiography for detection of pulmonary emboli: comparison between equi-iodine doses of iomeprol 400 mgI/mL and iodixanol 320 mgI/mL. [2009.06]
OBJECTIVES: To compare iomeprol 400 and iodixanol 320 in pulmonary artery MDCTA in subjects with suspected pulmonary embolism... CONCLUSION: The greater iodine delivery rate achievable with iomeprol 400 compared to iodixanol-320 at equi-iodine dose and injection rate permits consistently greater attenuation at all levels of the pulmonary arterial tree.
Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. [2006.09.05]
OBJECTIVES: This study sought to compare the nephrotoxicity of iodixanol and ioxaglate in patients with renal impairment undergoing coronary angiography. BACKGROUND: Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium (IOCM), may be less nephrotoxic than low-osmolar contrast media (LOCM) in high-risk patients... CONCLUSIONS: The IOCM iodixanol was significantly less nephrotoxic than ioxaglate, an ionic, dimeric LOCM. (The RECOVER Trial; http://clinicaltrials.gov; NCT00247325).
Intravenous contrast material administration at helical 16-detector row CT coronary angiography: effect of iodine concentration on vascular attenuation. [2005.08]
The institutional review board approved this study, and all patients gave written informed consent. One hundred twenty-five patients scheduled to undergo retrospectively electrocardiographically gated 16-detector row computed tomographic coronary angiography were prospectively randomized into the following five groups with respect to the intravenous administration of a 140-mL bolus of contrast material at 4 mL/sec: group 1 (iohexol [300 mg of iodine per milliliter]), group 2 (iodixanol [320 mg I/mL]), group 3 (iohexol [350 mg I/mL]), group 4 (iomeprol [350 mg I/mL]), and group 5 (iomeprol [400 mg I/mL])...
Coronary stent evaluation with coronary computed tomographic angiography:
comparison between low-osmolar, high-iodine concentration iomeprol-400 and
iso-osmolar, lower-iodine concentration iodixanol-320. 
stents with MDCT-CA... CONCLUSIONS: Iodixanol-320 provides better image quality of coronary stents,
Clinical Trials Related to Visipaque (Iodine Intravascular)
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography [Recruiting]
It is well known that X-ray contrast media can affect kidney function in some patients,
especially when administered intra-arterially, and patients who already suffer from reduced
kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use
low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast
media-induced nephropathy. However, little is known about the intravenous use of X-ray
contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose
of this study is to evaluate and compare the effects on kidney function of two contrast
media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney
damage associated with the injection of contrast media. Due to the iso-osmolar feature, it
is expected less influence on renal function following administration of iodixanol. A
standard hydration procedure, based on available guidelines will be given to all patients to
prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be
measured before and up to 7 days after contrast media administration to evaluate the effects
on renal function.
Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients [Recruiting]
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN)
following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque
320) in patients with chronic kidney disease undergoing coronary angiography.
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography [Recruiting]
The purpose of this study is to evaluate and compare overall patient comfort profile between
an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast
media (LOCM), iopamidol 370 mg I/mL in patients undergoing arteriography of peripheral
RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography [Completed]
In the treatment of coronary heart disease which is the major cause of heart attack, direct
mechanical treatment with catheters such as the coronary angiography,coronary balloon
intervention and stenting intervention are the mainstay of therapy in recent years. In that
procedures, we should use the contrast media, and it may cause kidney toxicity especially in
the patients with underlying kidney disease and decreased kidney function. We intended to
find out which contrast agent has less kidney toxicity in the catheter based treatment of
coronary arterial diseases in patients with underlying decreased kidney function
A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients [Recruiting]
The investigators intend to find out which contrast agent has less kidney toxicity in renal
impaired patients undergoing cardiac angiography or percutaneous coronary intervention
Reports of Suspected Visipaque (Iodine Intravascular) Side Effects
Renal Failure Acute (10),
Infusion Site Extravasation (7),
Lactic Acidosis (6),
Abdominal Pain (5),
Confusional State (5), more >>
Page last updated: 2015-02-11